Dynavax Technologies Profit Margin 2010-2022 | DVAX
Current and historical gross margin, operating margin and net profit margin for Dynavax Technologies (DVAX) over the last 10 years. Profit margin can be defined as the percentage of revenue that a company retains as income after the deduction of expenses. Dynavax Technologies net profit margin as of December 31, 2022 is 40.56%.
| Dynavax Technologies Annual Profit Margins |
| Dynavax Technologies Quarterly Profit Margins |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$1.246B |
$0.723B |
|
Dynavax Technologies discovers, develops, and intends to commercialize innovative products to treat and prevent allergies, infectious diseases, and chronic inflammatory diseases using versatile, proprietary approaches that alter immune system responses in highly specific ways. Dynavax's clinical development programs are based on immunostimulatory sequences which are short DNA sequences that enhance the ability of the immune system to fight disease and control chronic inflammation.
|
